Showing studies related to your query18 results shown

Studies (18 shown)

NCT06161025PHASE2, PHASE3RECRUITING

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor · Daiichi SankyoCondition · Solid CancerIntervention · R-DXd, PaclitaxelUpdated May 2026
NCT06864169PHASE2ACTIVE_NOT_RECRUITING

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Sponsor · Merck Sharp & Dohme LLCCondition · Gastrointestinal CancerIntervention · Raludotatug Deruxtecan (R-DXd)Updated Apr 2026
NCT06780098PHASE2RECRUITING

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Sponsor · Merck Sharp & Dohme LLCCondition · Lung NeoplasmIntervention · R-DXD, I-DXDUpdated May 2026
NCT06925737PHASE3RECRUITING

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Sponsor · Merck Sharp & Dohme LLCCondition · Prostate Cancer, Prostatic NeoplasmsIntervention · Ifinatamab deruxtecan, DocetaxelUpdated May 2026
NCT06660654PHASE2ACTIVE_NOT_RECRUITING

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Sponsor · Daiichi SankyoCondition · Advanced Solid Tumor, Metastatic Solid TumorsIntervention · Raludotatug deruxtecanUpdated May 2026
NCT04938817PHASE1, PHASE2ACTIVE_NOT_RECRUITING

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Sponsor · Merck Sharp & Dohme LLCCondition · Small Cell Lung CarcinomaIntervention · coformulation pembrolizumab/quavonlimab, lenvatinibUpdated May 2026
NCT06780085PHASE2RECRUITING

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Sponsor · Merck Sharp & Dohme LLCCondition · Carcinoma, Non-Small-Cell LungIntervention · Raludotatug Deruxtecan, Ifinatamab DeruxtecanUpdated May 2026
NCT06843447PHASE1, PHASE2RECRUITING

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Sponsor · Merck Sharp & Dohme LLCCondition · Ovarian Cancer RecurrentIntervention · Raludotatug Deruxtecan, CarboplatinUpdated May 2026
NCT04619004PHASE2ACTIVE_NOT_RECRUITING

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Sponsor · Daiichi SankyoCondition · Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorIntervention · Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)Updated May 2026
NCT05408845PHASE2RECRUITING

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Sponsor · NRG OncologyCondition · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland CarcinomaIntervention · Biopsy Procedure, Biospecimen CollectionUpdated May 2026
NCT05555732PHASE3ACTIVE_NOT_RECRUITING

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Sponsor · Daiichi SankyoCondition · Metastatic Non Small Cell Lung CancerIntervention · Datopotamab Deruxtecan, PembrolizumabUpdated Mar 2026
NCT04616560PHASE2SUSPENDED

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Sponsor · National Cancer Institute (NCI)Condition · Osteosarcoma, Recurrent OsteosarcomaIntervention · Biospecimen Collection, Echocardiography TestUpdated May 2026
NCT06644781PHASE3RECRUITING

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Sponsor · Daiichi SankyoCondition · Esophageal Squamous Cell CarcinomaIntervention · Ifinatamab deruxtecan, DocetaxelUpdated Jan 2026
NCT04707248PHASE1ACTIVE_NOT_RECRUITING

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Sponsor · Daiichi SankyoCondition · Renal Cell Carcinoma, Ovarian TumorIntervention · DS-6000a, DS-6000aUpdated Jul 2025
NCT05868226PHASE1RECRUITING

PRE-I-SPY Phase I/Ib Oncology Platform Program

Sponsor · QuantumLeap Healthcare CollaborativeCondition · HER2-positive Breast Cancer, Metastatic CancerIntervention · ALX148, Fam-Trastuzumab Deruxtecan-NxkiUpdated Apr 2025
NCT06088056PHASE2NOT_YET_RECRUITING

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

Sponsor · Fudan UniversityCondition · Breast Cancer, Brain MetastasesIntervention · Combination use of SRT with T-DXdUpdated Oct 2023
NCT03248492PHASE2TERMINATED

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Sponsor · Daiichi SankyoCondition · Breast CancerIntervention · DS-8201aUpdated Jun 2025
NCT05919212NAUNKNOWN

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Sponsor · Fondazione Policlinico Universitario Agostino Gemelli IRCCSCondition · Metastatic Breast CancerIntervention · HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitmentUpdated Apr 2024
Showing top 18 results. See all 18 results on CT.gov →